- Home
- ZNTL vs BLNK Comparison
ZNTL vs BLNK Comparison
Compare ZNTL & BLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- BLNK
- Stock Information
- Founded
- ZNTL 2014
- BLNK 2009
- Country
- ZNTL United States
- BLNK United States
- Employees
- ZNTL N/A
- BLNK N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- BLNK Industrial Specialties
- Sector
- ZNTL Health Care
- BLNK Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- BLNK Nasdaq
- Market Cap
- ZNTL 238.2M
- BLNK 295.1M
- IPO Year
- ZNTL 2020
- BLNK N/A
- Fundamental
- Price
- ZNTL $3.12
- BLNK $2.08
- Analyst Decision
- ZNTL Buy
- BLNK Strong Buy
- Analyst Count
- ZNTL 7
- BLNK 7
- Target Price
- ZNTL $10.86
- BLNK $5.79
- AVG Volume (30 Days)
- ZNTL 1.2M
- BLNK 4.4M
- Earning Date
- ZNTL 11-04-2024
- BLNK 11-07-2024
- Dividend Yield
- ZNTL N/A
- BLNK N/A
- EPS Growth
- ZNTL N/A
- BLNK N/A
- EPS
- ZNTL N/A
- BLNK N/A
- Revenue
- ZNTL $40,560,000.00
- BLNK $156,918,000.00
- Revenue This Year
- ZNTL N/A
- BLNK $6.96
- Revenue Next Year
- ZNTL N/A
- BLNK $31.64
- P/E Ratio
- ZNTL N/A
- BLNK N/A
- Revenue Growth
- ZNTL N/A
- BLNK 66.29
- 52 Week Low
- ZNTL $2.83
- BLNK $1.53
- 52 Week High
- ZNTL $18.24
- BLNK $4.66
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- BLNK 59.80
- Support Level
- ZNTL $2.92
- BLNK $1.63
- Resistance Level
- ZNTL $3.23
- BLNK $2.14
- Average True Range (ATR)
- ZNTL 0.17
- BLNK 0.12
- MACD
- ZNTL 0.00
- BLNK 0.03
- Stochastic Oscillator
- ZNTL 38.33
- BLNK 86.67
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.